Yizhen Lv

Ms. Yizhen Lv

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 October 2020 in Journal of Drug Targeting
Verified
Journal Article
Closed access
AFAbebe Feyissa
Abebe Feyissa
JLJian Lei
Jian Lei
HDHuan Deng
Huan Deng
YLYizhen Lv
Yizhen Lv
Jing HanJing Han
Jing Han
LZLei Zhang
Lei Zhang
Chondroitin sulphate captured an increasing amount of attention in the field of drug delivery systems. Nanoparticles and chondroitin sulphate were combined in different ways to form effective target nanocarriers. The study aimed to evaluate the biomedical application of chondroitin sulphate with nanoparticles in drug delivery systems. We searched PubMed, Google Scholar, and MEDLINE for studies that included data for the application of chondroitin sulphate and nanoparticles in targeting drug delivery published in English up to 25 February 2020. OHAT (Office of Health Assessment and Translation) Risk-of-Bias Tool was used to assessing the quality and risk of bias of each study. We performed a qualitative synthesis of findings from included studies. The toxicity of developed drugs has been evaluated using cell viability percentage and 50% inhibitory concentration of drugs. Twenty original articles reported the application of chondroitin sulphate on drug delivery systems were selected. Drug loading and encapsulation efficiency were from 2% to 16.1% and from 39.50% to 93.97%, respectively. The drug release was fast at start time and followed by a slow and sustain released stage. The risk of bias was rated as high in two out of twenty studies. Most of the studies presented baseline characteristics and outcomes appropriately.

12 August 2022 in Cells
Verified
Journal Article
Open access
PDF file
Jing HanJing Han
Jing Han
HDHuan Deng
Huan Deng
YLYizhen Lv
Yizhen Lv
XXXiang Xiao
Xiang Xiao
YZYan Zhao
Yan Zhao
MLMikko Lammi
Mikko Lammi
Glycoproteins are involved in the development of many diseases, while the type and content of N-glycoproteins in the cartilage of osteoarthritis (OA) and Kashin–Beck disease (KBD) are still unclear. This research aims to identify N-glycoproteins in knee cartilage patients with OA and KBD compared with normal control (N) adults. The cartilage samples were collected from gender- and age-matched OA (n = 9), KBD (n = 9) patients, and N (n = 9) adults. Glycoproteomics and label-free liquid chromatography-tandem mass spectrometry (LC-MS/MS) obtained N-glycoproteins of KBD and OA. A total of 594 N-glycoproteins and 1146 N-glycosylation peptides were identified. The identified data were further compared and analyzed with Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Protein–Protein Interactions (PPI). Pairwise comparison of the glycoproteins detected in the three groups showed that integrin beta-1 (ITGB1), collagen alpha-1 (II) chain (COL2A1), collagen alpha-1 (VII) chain (COL7A1), carbohydrate sulfotransferase 3 (CHST-3), carbohydrate sulfotransferase 4 (CHST-4), thrombospondin 2 (THBS2), bone morphogenetic protein 8A (BMP8A), tenascin-C (TNC), lysosome-associated membrane protein (LAMP2), and beta-glucuronidase (GUSB) were significantly differentially expressed. GO results suggested N-glycoproteins mainly belonged to protein metabolic process, single-multicellular and multicellular organism process, cell adhesion, biological adhesion, and multicellular organism development. KEGG and PPI results revealed that key N-glycoproteins were closely related to pathways for OA and KBD, such as phagosome, ECM-receptor interaction, lysosome, focal adhesion, protein digestion, and absorption. These results reflected glycoprotein expression for OA and KBD in the process of ECM degradation, material transport, cell–cell or cell–ECM interaction, and information transduction. These key significantly differentially expressed N-glycoproteins and pathways lead to the degeneration and degradation of the cartilage of OA and KBD mainly by disrupting the synthesis and catabolism of basic components of ECM and chondrocytes and interfering with the transfer of material or information. The key N-glycoproteins or pathways in this research are potential targets for pathological mechanisms and therapies of OA and KBD.


1 June 2026 in Hypertension
Verified
Journal Article
Closed access
YLYizhen Lv
Yizhen Lv
WBWenming Bian
Wenming Bian
YLYezhou Liu
Yezhou Liu
YLYetong Liu
Yetong Liu
JZJiaheng Zhang
Jiaheng Zhang
CLChao Li
Chao Li
BACKGROUND: Contemporary hypertension guidelines emphasize individualized blood pressure (BP) management, often incorporating age; yet chronological age alone may be insufficient to guide optimal treatment. The frailty index offers a multidimensional measure of biological aging and may better guide BP management. METHODS: We pooled participant-level data from SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes). The frailty index was calculated using a 31-item Rockwood cumulative-deficit model, with frailty defined as a frailty index >0.21. Participants were also categorized by age (<65 versus ≥65 years). Systolic BP (SBP) time in target range (TTR) was calculated using linear interpolation across 10 mm Hg intervals. Restricted cubic splines and stratified Cox models were used to assess the association between TTR within predefined SBP targets and major adverse cardiovascular events. RESULTS: A total of 19 230 participants were included in the analysis (mean age, 65.2 years; 49.0% women; 68.2% classified as frail). Restricted cubic spline analyses showed a J-shaped relationship between average SBP and major adverse cardiovascular events, with clearer separation by frailty than by age. Among frail individuals, greater time spent within SBP intervals between 110 and 140 mm Hg was associated with lower major adverse cardiovascular event risk (hazard ratios per 10% increase in TTR, 0.92–0.94), whereas among nonfrail individuals, greater time spent below 130 mm Hg was associated with lower risk (hazard ratios per 10% increase in TTR, 0.89–0.98). Age demonstrated limited discrimination. Findings were consistent in separate analyses of SPRINT and ACCORD. CONCLUSIONS: The frailty index, rather than chronological age, more accurately discriminates optimal SBP targets in hypertensive patients, whereas chronological age may remain a more practical tool in resource-limited settings.

18 June 2025 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
JZJiaheng Zhang
Jiaheng Zhang
HXHaibao Xu
Haibao Xu
YLYezhou Liu
Yezhou Liu
YLYizhen Lv
Yizhen Lv
WBWenming Bian
Wenming Bian
CLChao Li
Chao Li
Through the utilization of the time in target range (TTR), our study aims to reassess the differential risks of cardiorenal diseases associated with inconsistent pre-diabetes criteria, as defined by the World Health Organization (WHO) and the American Diabetes Association (ADA). We performed a pooled analysis from the Atherosclerosis Risk in Communities study and the Multi-Ethnic Study of Atherosclerosis study. TTR for each patient was calculated using linear interpolation before the outcome. Cox regression models were used to assess the association of FPG TTR with the clinical outcomes. A total of 14 346 patients were included. Using adjusted Cox regression model, both ADA (HR: 1.17, 95 % CI: 1.09 to 1.25) and WHO (HR: 1.37, 95 % CI: 1.21 to 1.57) defined pre-diabetes range were associated with an increased risk of major adverse cardiovascular events (MACE). Additionally, individuals with FPG levels in the range between the two standards (100-110 mg/dL) also had a higher risk of MACE (HR: 1.24, 95 % CI: 1.09 to 1.40). Meanwhile, no significant relation was found between FPG threshold and Chronic kidney disease (CKD). The threshold defined by the ADA guidelines serves to protect cardiovascular health across a broader population while not increasing the risk of CKD.

1 March 2026 in Circulation: Population Health and Outcomes
Verified
Journal Article
Closed access
YLYizhen Lv
Yizhen Lv
JZJiaheng Zhang
Jiaheng Zhang
YLYamei Liu
Yamei Liu
YLYezhou Liu
Yezhou Liu
WBWenming Bian
Wenming Bian
CLChao Li
Chao Li
BACKGROUND: Inconsistent selection of reference groups may contribute to inconclusive blood pressure control targets for patients with hypertension. This study aims to identify optimal systolic blood pressure (SBP) targets for individuals with and without cardiovascular disease (CVD) by employing a novel metric combining blood pressure magnitude and duration. METHODS: We conducted a secondary analysis of individual-level data from 4 clinical trials. Participants aged >80 years, with prevalent heart failure, or with missing follow-up SBP measurements or CVD history were excluded. The proportion of time-in-target range (TTR) was estimated using linear interpolation to quantify longitudinal SBP changes across predefined SBP ranges. Associations between TTR and major adverse cardiovascular events were assessed using stratified Cox proportional hazards models, analyzed separately by CVD history, and stratified by study trials, with hazard ratios (HRs) estimated per 10% increase in TTR. Lower TTR within the same target served as the implicit reference. RESULTS: Among 59 727 participants included in the analysis, the mean age was 65.8 (SD, 6.9) years, 52.3% were men, and 24 524 (41.1%) had a history of CVD. Higher TTR within SBP ranges of 110 to 140 mm Hg was consistently associated with a lower risk of major adverse cardiovascular events in participants with and without CVD. For SBP of 110 to 120 mm Hg, HRs were 0.89 (95% CI, 0.86–0.92) in participants without CVD and 0.93 (95% CI, 0.90–0.95) among those with CVD; corresponding HRs were 0.86 (95% CI, 0.83–0.88) and 0.90 (95% CI, 0.88–0.92) for 120 to 130 mm Hg, and 0.94 (95% CI, 0.92–0.96) and 0.93 (95% CI, 0.91–0.95) for 130 to 140 mm Hg. SBP ≥150 mm Hg was associated with increased major adverse cardiovascular event risk in both groups, whereas SBP <110 mm Hg was associated with reduced risk only in participants without CVD (HR, 0.91 [95% CI, 0.86–0.97]) and not among those with CVD (HR, 1.02 [95% CI, 0.98–1.06]). CONCLUSIONS: Restricted cubic spline analyses demonstrated a J-shaped association between achieved SBP and major adverse cardiovascular event irrespective of CVD history. Maintaining SBP within 110 to 140 mm Hg was similarly associated with lower cardiovascular risk in patients with and without CVD. Risk appeared lowest when SBP was between 120 and 130 mm Hg, while an SBP target <110 mm Hg may offer additional benefit among patients without CVD.